targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000061918 | EFO_0004278 | NCT03079102 | Terminated | 2 | 2017-08-21 | Terminated | stopped | null | null | Phase II+ | 77,309,411,797 | Slow enrollment and planned change of institution by PI | Phase 2 | 21/08/2017 | Terminated | 25/05/2021 | 02/06/2020 | Study_Staff_Moved | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000061918 | EFO_0004278 | NCT03079102 | Terminated | 2 | 2017-08-21 | Terminated | stopped | null | null | Phase II+ | 77,309,411,797 | Slow enrollment and planned change of institution by PI | Phase 2 | 21/08/2017 | Terminated | 25/05/2021 | 02/06/2020 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 2 | LoF tolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000061918 | EFO_0004278 | NCT03079102 | Terminated | 2 | 2017-08-21 | Terminated | stopped | null | null | Phase II+ | 77,309,411,797 | Slow enrollment and planned change of institution by PI | Phase 2 | 21/08/2017 | Terminated | 25/05/2021 | 02/06/2020 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000061918 | EFO_0004278 | NCT03079102 | Terminated | 2 | 2017-08-21 | Terminated | stopped | null | null | Phase II+ | 77,309,411,797 | Slow enrollment and planned change of institution by PI | Phase 2 | 21/08/2017 | Terminated | 25/05/2021 | 02/06/2020 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT01719835 | Active, not recruiting | 2 | 2012-03-01 | null | null | null | null | Phase II+ | 841,813,591,844 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 1 | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT01719835 | Active, not recruiting | 2 | 2012-03-01 | null | null | null | null | Phase II+ | 841,813,591,844 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT01719835 | Active, not recruiting | 2 | 2012-03-01 | null | null | null | null | Phase II+ | 841,813,591,844 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT01529827 | Completed | 2 | 2012-02-28 | null | null | null | null | Phase II+ | 360,777,253,609 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 1 | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT01529827 | Completed | 2 | 2012-02-28 | null | null | null | null | Phase II+ | 360,777,253,609 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT01529827 | Completed | 2 | 2012-02-28 | null | null | null | null | Phase II+ | 360,777,253,609 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT03593018 | Active, not recruiting | 3 | 2018-11-09 | null | null | null | Phase III+ | Phase II+ | 996,432,412,815 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 1 | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT03593018 | Active, not recruiting | 3 | 2018-11-09 | null | null | null | Phase III+ | Phase II+ | 996,432,412,815 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000062822 | EFO_0000255 | NCT03593018 | Active, not recruiting | 3 | 2018-11-09 | null | null | null | Phase III+ | Phase II+ | 996,432,412,815 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in many | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000065518 | EFO_0001361 | NCT01352026 | Withdrawn | 2 | 2011-05-01 | Withdrawn | stopped | null | null | Phase II+ | 429,496,730,634 | Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials | Phase 2 | 31/05/2011 | Withdrawn | 06/08/2012 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | EFO_0001361 | NCT01352026 | Withdrawn | 2 | 2011-05-01 | Withdrawn | stopped | null | null | Phase II+ | 429,496,730,634 | Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials | Phase 2 | 31/05/2011 | Withdrawn | 06/08/2012 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | EFO_0001361 | NCT01352026 | Withdrawn | 2 | 2011-05-01 | Withdrawn | stopped | null | null | Phase II+ | 429,496,730,634 | Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials | Phase 2 | 31/05/2011 | Withdrawn | 06/08/2012 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | EFO_0001361 | NCT03617458 | Recruiting | 2 | 2018-08-23 | null | null | null | null | Phase II+ | 1,683,627,181,632 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | EFO_0001361 | NCT03617458 | Recruiting | 2 | 2018-08-23 | null | null | null | null | Phase II+ | 1,683,627,181,632 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | EFO_0001361 | NCT03617458 | Recruiting | 2 | 2018-08-23 | null | null | null | null | Phase II+ | 1,683,627,181,632 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02068443 | Completed | 3 | 2014-02-01 | null | null | null | Phase III+ | Phase II+ | 103,079,215,891 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02068443 | Completed | 3 | 2014-02-01 | null | null | null | Phase III+ | Phase II+ | 103,079,215,891 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02068443 | Completed | 3 | 2014-02-01 | null | null | null | Phase III+ | Phase II+ | 103,079,215,891 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05167513 | Recruiting | 4 | 2021-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 103,079,216,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05167513 | Recruiting | 4 | 2021-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 103,079,216,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05167513 | Recruiting | 4 | 2021-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 103,079,216,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089205 | Completed | 1 | null | null | null | null | null | null | 103,079,217,061 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089205 | Completed | 1 | null | null | null | null | null | null | 103,079,217,061 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089205 | Completed | 1 | null | null | null | null | null | null | 103,079,217,061 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00698230 | Completed | 2 | 2008-05-01 | null | null | null | null | Phase II+ | 188,978,562,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00698230 | Completed | 2 | 2008-05-01 | null | null | null | null | Phase II+ | 188,978,562,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00698230 | Completed | 2 | 2008-05-01 | null | null | null | null | Phase II+ | 188,978,562,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04854512 | Recruiting | 3 | 2021-05-18 | null | null | null | Phase III+ | Phase II+ | 188,978,562,531 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04854512 | Recruiting | 3 | 2021-05-18 | null | null | null | Phase III+ | Phase II+ | 188,978,562,531 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04854512 | Recruiting | 3 | 2021-05-18 | null | null | null | Phase III+ | Phase II+ | 188,978,562,531 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00941161 | Completed | 4 | 2009-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 188,978,562,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00941161 | Completed | 4 | 2009-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 188,978,562,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00941161 | Completed | 4 | 2009-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 188,978,562,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00184626 | Completed | 4 | 2004-09-10 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,430,760 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00184626 | Completed | 4 | 2004-09-10 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,430,760 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00184626 | Completed | 4 | 2004-09-10 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,430,760 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02638805 | Completed | 3 | 2015-12-01 | null | null | null | Phase III+ | Phase II+ | 206,158,432,065 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02638805 | Completed | 3 | 2015-12-01 | null | null | null | Phase III+ | Phase II+ | 206,158,432,065 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02638805 | Completed | 3 | 2015-12-01 | null | null | null | Phase III+ | Phase II+ | 206,158,432,065 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01477853 | Terminated | 3 | 2011-10-24 | Terminated | stopped | null | Phase III+ | Phase II+ | 223,338,299,655 | The study was terminated early by the Sponsor for business reasons. | Phase 3 | 24/10/2011 | Terminated | 26/07/2018 | 04/12/2012 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01477853 | Terminated | 3 | 2011-10-24 | Terminated | stopped | null | Phase III+ | Phase II+ | 223,338,299,655 | The study was terminated early by the Sponsor for business reasons. | Phase 3 | 24/10/2011 | Terminated | 26/07/2018 | 04/12/2012 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01477853 | Terminated | 3 | 2011-10-24 | Terminated | stopped | null | Phase III+ | Phase II+ | 223,338,299,655 | The study was terminated early by the Sponsor for business reasons. | Phase 3 | 24/10/2011 | Terminated | 26/07/2018 | 04/12/2012 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04218734 | Completed | 3 | 2020-01-14 | null | null | null | Phase III+ | Phase II+ | 223,338,299,707 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04218734 | Completed | 3 | 2020-01-14 | null | null | null | Phase III+ | Phase II+ | 223,338,299,707 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04218734 | Completed | 3 | 2020-01-14 | null | null | null | Phase III+ | Phase II+ | 223,338,299,707 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01596504 | Completed | 2 | 2012-05-01 | null | null | null | null | Phase II+ | 223,338,301,062 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01596504 | Completed | 2 | 2012-05-01 | null | null | null | null | Phase II+ | 223,338,301,062 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01596504 | Completed | 2 | 2012-05-01 | null | null | null | null | Phase II+ | 223,338,301,062 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02623998 | Completed | 3 | 2016-07-09 | null | null | null | Phase III+ | Phase II+ | 223,338,301,209 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02623998 | Completed | 3 | 2016-07-09 | null | null | null | Phase III+ | Phase II+ | 223,338,301,209 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02623998 | Completed | 3 | 2016-07-09 | null | null | null | Phase III+ | Phase II+ | 223,338,301,209 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00265746 | Withdrawn | 4 | 2005-11-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 223,338,301,340 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00265746 | Withdrawn | 4 | 2005-11-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 223,338,301,340 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00265746 | Withdrawn | 4 | 2005-11-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 223,338,301,340 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00885378 | Completed | 3 | 2009-05-01 | null | null | null | Phase III+ | Phase II+ | 249,108,104,959 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00885378 | Completed | 3 | 2009-05-01 | null | null | null | Phase III+ | Phase II+ | 249,108,104,959 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00885378 | Completed | 3 | 2009-05-01 | null | null | null | Phase III+ | Phase II+ | 249,108,104,959 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00347100 | Completed | 4 | 2006-06-01 | null | null | Phase IV | Phase III+ | Phase II+ | 266,287,972,676 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00347100 | Completed | 4 | 2006-06-01 | null | null | Phase IV | Phase III+ | Phase II+ | 266,287,972,676 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00347100 | Completed | 4 | 2006-06-01 | null | null | Phase IV | Phase III+ | Phase II+ | 266,287,972,676 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00279045 | Completed | 3 | 2000-01-03 | null | null | null | Phase III+ | Phase II+ | 266,287,973,332 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00279045 | Completed | 3 | 2000-01-03 | null | null | null | Phase III+ | Phase II+ | 266,287,973,332 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00279045 | Completed | 3 | 2000-01-03 | null | null | null | Phase III+ | Phase II+ | 266,287,973,332 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01206647 | Unknown status | 4 | 2010-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 292,057,776,872 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01206647 | Unknown status | 4 | 2010-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 292,057,776,872 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01206647 | Unknown status | 4 | 2010-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 292,057,776,872 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00819741 | Completed | 4 | 2009-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 309,237,647,394 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00819741 | Completed | 4 | 2009-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 309,237,647,394 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00819741 | Completed | 4 | 2009-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 309,237,647,394 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00605475 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 309,237,647,488 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00605475 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 309,237,647,488 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00605475 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 309,237,647,488 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00420511 | Completed | 2 | 2007-01-01 | null | null | null | null | Phase II+ | 326,417,514,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00420511 | Completed | 2 | 2007-01-01 | null | null | null | null | Phase II+ | 326,417,514,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00420511 | Completed | 2 | 2007-01-01 | null | null | null | null | Phase II+ | 326,417,514,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04392557 | Recruiting | 4 | 2020-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 326,417,516,021 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04392557 | Recruiting | 4 | 2020-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 326,417,516,021 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04392557 | Recruiting | 4 | 2020-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 326,417,516,021 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00106340 | Completed | 3 | 2005-03-01 | null | null | null | Phase III+ | Phase II+ | 326,417,516,191 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00106340 | Completed | 3 | 2005-03-01 | null | null | null | Phase III+ | Phase II+ | 326,417,516,191 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00106340 | Completed | 3 | 2005-03-01 | null | null | null | Phase III+ | Phase II+ | 326,417,516,191 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01181674 | Completed | 4 | 2011-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 326,417,516,207 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01181674 | Completed | 4 | 2011-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 326,417,516,207 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01181674 | Completed | 4 | 2011-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 326,417,516,207 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02501850 | Unknown status | 4 | 2014-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 352,187,318,736 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02501850 | Unknown status | 4 | 2014-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 352,187,318,736 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02501850 | Unknown status | 4 | 2014-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 352,187,318,736 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01917656 | Completed | 4 | 2014-01-09 | null | null | Phase IV | Phase III+ | Phase II+ | 352,187,318,850 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01917656 | Completed | 4 | 2014-01-09 | null | null | Phase IV | Phase III+ | Phase II+ | 352,187,318,850 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01917656 | Completed | 4 | 2014-01-09 | null | null | Phase IV | Phase III+ | Phase II+ | 352,187,318,850 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00318656 | Completed | 4 | 2005-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 377,957,122,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00318656 | Completed | 4 | 2005-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 377,957,122,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00318656 | Completed | 4 | 2005-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 377,957,122,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02091362 | Completed | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 377,957,122,201 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02091362 | Completed | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 377,957,122,201 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02091362 | Completed | 2 | 2014-03-01 | null | null | null | null | Phase II+ | 377,957,122,201 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |